Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era?

摘要: Abstract Background Low-dose all-transretinoic acid (LD-ATRA) has shown similar peak plasma concentrations and a mean area under the concentration time curve in comparison with standard doses of ATRA. We evaluated efficacy LD-ATRA plus anthracycline-based chemotherapy patients newly diagnosed acute promyelocytic leukemia (APL). Patients Methods APL during period 2002 to 2014 were included. They received ATRA 25 mg/m 2 anthracycline (doxorubicin or mitoxantrone) as induction chemotherapy, followed by 3 consolidations maintenance therapy intermittent oral for years. Results Twenty-two median age 28 years (range, 18-55 years) included; 17 (77%) low-risk group. Complete remission occurred 86%, early death rate was 9%. At follow-up 32 months 4-126 months) disease-free survival (DFS) 75% overall (OS) relapse 27% entire period. Conclusion is safe effective achieving CR APL. The that treatment doses, but it appears be inferior preventing relapses.